Alice L. Yu
Led the trial proving that an anti-GD2 antibody improves survival in high-risk neuroblastoma.
Pediatric oncologist and study chair of COG ANBL0032, the randomised trial of ch14.18 (dinutuximab) with GM-CSF and IL-2 that established anti-GD2 immunotherapy in high-risk neuroblastoma.
| Title | Journal | Year |
|---|---|---|
| Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma | New England Journal of Medicine | 2010 |
| Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032 | Clinical Cancer Research | 2021 |
Pages like this
not linked directly; found by shared links- PersonJulie R. Park
Shares COG ANBL0032, Dinutuximab (ch14.18) / dinutuximab beta, GD2 (disialoganglioside), Children's Oncology Group (COG).
- InstitutionUniversity of Wisconsin Carbone Cancer Center
Shares Dinutuximab (ch14.18) / dinutuximab beta, GD2 (disialoganglioside), Children's Oncology Group (COG), Neuroblastoma (paediatric).
- PairingAnti-GD2 antibody + irinotecan-temozolomide (chemoimmunotherapy)
Shares Dinutuximab (ch14.18) / dinutuximab beta, GD2 (disialoganglioside), Neuroblastoma (paediatric).
- PairingCaution: IL-2 added to anti-GD2 therapy
Shares Dinutuximab (ch14.18) / dinutuximab beta, Neuroblastoma (paediatric).
- CompanyY-mAbs Therapeutics
Shares GD2 (disialoganglioside), Neuroblastoma (paediatric).
- ProductNaxitamab
Shares GD2 (disialoganglioside), Monoclonal antibodies, Neuroblastoma (paediatric).
- InstitutionTexas Children's Cancer and Hematology Center
Shares GD2 (disialoganglioside), Children's Oncology Group (COG), Neuroblastoma (paediatric).
- IdeaMake paediatric combination studies part of every relevant adult cancer drug approval
Shares Children's Oncology Group (COG), Neuroblastoma (paediatric).